» Articles » PMID: 12200646

Short-term Omeprazole Treatment Does Not Influence Biochemical Parameters of Bone Turnover in Children

Overview
Specialty Pathology
Date 2002 Aug 30
PMID 12200646
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric proton pump inhibitors are widely used in the treatment of dyspeptic problems and for the eradication of H. pylori infection. Data are not available on whether omeprazole, a representative of proton pump inhibitors, influences the function of osteoclastic H+-pump in children. We studied the impact of short-term omeprazole administration on the biochemical parameters of bone turnover in pediatric patients. Urinary calcium excretion, serum total alkaline phosphatase activity, collagen type 1 crosslinked C-telopeptide, and osteocalcin levels were determined in 34 children [20 girls (9 prepubertal) and 14 boys (6 prepubertal)] before and after 2 weeks of omeprazole treatment at a dose of 20 mg/day. The measured parameters were within the healthy reference range in each patient. None of them altered during the study in any age or in any gender. We conclude that omeprazole, at a dose of 20 mg/day, does not significantly influence the investigated biochemical parameters of osteoclast and osteoblast function in pediatric patients.

Citing Articles

Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?.

Aasarod K, Mosti M, Finstad M, Stunes A, Fossmark R, Syversen U Bone Rep. 2021; 14:101095.

PMID: 34095362 PMC: 8167151. DOI: 10.1016/j.bonr.2021.101095.


Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo.

Li Y, Chen F, Liu T, Cai Z, Chen K, Tang G Stem Cells Int. 2020; 2020:8829212.

PMID: 33354217 PMC: 7737473. DOI: 10.1155/2020/8829212.


Effect of proton pump inhibitors on dental implants: A systematic review and meta-analysis.

Vinnakota D, Kamatham R J Indian Prosthodont Soc. 2020; 20(3):228-236.

PMID: 33223692 PMC: 7654198. DOI: 10.4103/jips.jips_283_19.


Bone Health in Glomerular Kidney Disease.

Glenn D, Denburg M Curr Osteoporos Rep. 2019; 17(6):570-579.

PMID: 31734906 PMC: 7153693. DOI: 10.1007/s11914-019-00531-z.


Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.

Poly T, Islam M, Yang H, Wu C, Li Y Osteoporos Int. 2018; 30(1):103-114.

PMID: 30539272 DOI: 10.1007/s00198-018-4788-y.